Amrutanjan Health Care Limited · NSE:AMRUTANJAN
Amrutanjan Health Care — H1 FY21 Earnings Presentation
15 slides from Amrutanjan Health Care's earnings presentation, Nov 12, 2020
Slide 1: Exchange filing cover letter for investor presentation
AHCL/ SE/ 43/2020-21 November 12 2020 The National Stock Exchange of India Limited BSE Limited “Exchange Plaza”, C-1, Block G Department of Corporate Services Bandra-Kurla Complex, Bandra (E) 1st Floor, Mumbai 400 051 P.J. Towers, Dalal Street, ISIN: INEO98F01031 Mumbai 400 001 Symbol : AMRUTANJAN S
Slide 2: Amrutanjan Health Care Limited Investor Presentation
Amrutanjan Health Care Limited Investor Presentation – Period Ended 30th September 2020 Date: 12th November 2020
Slide 3: Contents
Contents a. Business Update b. H1 FY21 Performance c. Q2 FY21 Performance d. Way Forward Investor Presentation | Quarter & Half Year Ended 30th September 2020 2
Slide 4: Business Update
Business Update Investor Presentation | Quarter & Half Year Ended 30th September 2020 3
Slide 5: Business Update
Business Update • Despite restrictions for field force during lockdown, our wholesale channel was picking up. This shows our Brand strength. • The increase in purchase volume by the distributors has contributed to the growth factor. • Consumers’ current preference of Balms over Tablets remains to be
Slide 6: H1 FY21 Performance
H1 FY21 Performance Investor Presentation | Quarter & Half Year Ended 30th September 2020 5
Slide 7: Financials – H1 FY21
Financials – H1 FY21 (Rs. in Crores) Gross Sales Profit Before Tax Profit After Tax 152.26 29.98 40.05 131.67 11.22 7.70 H1 FY21 H1 FY20 H1 FY21 H1 FY20 H1 FY21 H1 FY20 Growth: 15.64% Growth: 256.95% Growth: 289.35% Investor Presentation | Quarter & Half Year Ended 30th September 2020 6
Slide 8: Financials – H1 FY21 – OTC Division
Financials – H1 FY21 – OTC Division (Rs. in Crores) Gross Sales - OTC Costs: 144.82 • OTC sales has grown by 22.57% 118.15 during H1 even though April sales was affected due to Covid 19 lockdown. H1 FY21 H1 FY20 • Key raw material prices including Growth: 22.57% Menthol are lower when compared Gross
Slide 9: Financials – H1 FY21 – Beverage Division
Financials – H1 FY21 – Beverage Division (Rs. in Crores) Gross Sales - Beverages 12.19 7.05 Costs: • Gross Margin has improved by 267 basis points when H1 FY21 H1 FY20 compared to H1 FY20 mainly Growth: -42.17% due to product mix. Gross Sales - Electro Plus • Advertisement spends is at Rs.1.48 cr fo
Slide 10: Q2 FY21 Performance
Q2 FY21 Performance Investor Presentation | Quarter & Half Year Ended 30th September 2020 9
Slide 11: Financials – Q2 FY21
Financials – Q2 FY21 (Rs. in Crores) Gross Sales Profit Before Tax Profit After Tax 101.10 31.39 23.55 82.41 12.12 8.40 Q2 FY21 Q2 FY20 Q2 FY21 Q2 FY20 Q2 FY21 Q2 FY20 Growth: 22.68% Growth: 158.99% Growth: 180.36% Investor Presentation | Quarter & Half Year Ended 30th September 2020 10
Slide 12: Financials – Q2 FY21
Financials – Q2 FY21 (Rs. in Crores) Gross Sales - OTC Gross Sales - Comfy Gross Sales - Beverages 97.72 14.67 3.07 78.89 12.12 2.74 Q2 FY21 Q2 FY20 Q2 FY21 Q2 FY20 Q2 FY21 Q2 FY20 Growth: 23.87% Growth: 21.04% Growth: 12.04% Investor Presentation | Quarter & Half Year Ended 30th September 2020 11
Slide 13: Way Forward
Way Forward Investor Presentation | Quarter & Half Year Ended 30th September 2020 12
Slide 14: Way Forward
Way Forward We remain focused on executing our priorities: • Sustain the growth momentum in Q3 & Q4 • Expand distribution • Strengthen Beverage business • Grow E-Commerce vertical • Costs control Investor Presentation | Quarter & Half Year Ended 30th September 2020 13
Slide 15: Investor Presentation | Quarter & Half Year Ended 30th September 2020
Investor Presentation | Quarter & Half Year Ended 30th September 2020 14
Amrutanjan Health Care — H1 FY21 Earnings Presentation on 6ix